Relationship Between PVD and PAD in Patients with Risk Factors

Understanding PVD and PAD

PVD is a broader term that encompasses all vascular diseases affecting blood vessels outside the heart and brain, including both arterial and venous disorders 1
In clinical practice, PVD and PAD are often used interchangeably, with PAD being the most common manifestation of PVD, according to the American College of Cardiology 2, 3

Smoking is an exceptionally powerful etiologic risk factor for PAD, increasing risk by 2-6 fold, as reported by the American Heart Association 4
More than 80% of patients with PAD are current or former smokers, based on data from the American Heart Association 5
Smoking is 2-3 times more likely to cause PAD than coronary artery disease, according to the American Heart Association 4

Diabetes increases PAD risk by 2-4 fold, as stated by the American Diabetes Association 5
In the Framingham Heart Study, diabetes increased claudication risk by 3.5-fold in men and 8.6-fold in women, according to the American Heart Association 5
The risk of developing PAD is proportional to diabetes severity and duration, as reported by the American Diabetes Association 5
Diabetic patients with PAD are 7-15 times more likely to require amputation than non-diabetics with PAD, based on data from the American Diabetes Association 5

The presence of neuropathy in a patient with vascular disease increases the risk of foot ulceration and subsequent limb-threatening complications, as stated by the American Diabetes Association 6

PAD and CAD frequently coexist due to shared atherosclerotic pathophysiology, according to the American College of Cardiology 2
The prognosis of patients with PAD is characterized by increased risk for cardiovascular events due to concomitant coronary artery disease, as reported by the American College of Cardiology 2
Cardiovascular ischemic events are more frequent than ischemic limb events in PAD patients, based on data from the American College of Cardiology 2

In patients with risk factors (smoking, diabetes, CAD), PAD screening is recommended even without symptoms, as stated by the American Heart Association 7
The ankle-brachial index (ABI) is the most cost-effective tool for PAD detection, according to the American College of Cardiology 8
Arterial calcification in diabetic patients may falsely elevate ABI measurements, requiring alternative diagnostic approaches, as reported by the American Diabetes Association 6

Patients with PAD and multiple risk factors require aggressive risk factor modification, as stated by the American College of Cardiology 3
Treatment should include smoking cessation, lipid management, diabetes control, and antiplatelet therapy, according to the American College of Cardiology 3

Cigarette smoking is the most potent modifiable risk factor for peripheral arterial disease, increasing the risk by 2–6‑fold in exposed individuals. 9
Smoking confers a 2–3‑times higher likelihood of developing PAD than coronary artery disease, with a clear dose‑response relationship. 10
In the majority of epidemiologic cohorts, over 80 % of patients with claudication have a history of smoking at some point in their lives. 9
Smoking cessation yields rapid benefit: PAD incidence falls to the level of never‑smokers after approximately one year of abstinence. 10

Diabetes mellitus raises the overall risk of PAD by 2–4‑fold. 9
The magnitude of PAD risk is proportional to both the severity and duration of diabetes, especially for severe limb manifestations such as gangrene and ulceration. 10

Elevated total cholesterol combined with low high‑density lipoprotein (HDL) cholesterol are independently associated with a higher risk of PAD. 9
The total‑cholesterol‑to‑HDL ratio is the lipid metric most strongly linked to PAD development. 10

Hypertension is associated with a relative risk of 2.8 for incident PAD. 9
Both higher systolic and diastolic blood pressures correlate with a low ankle‑brachial index (< 0.90), an objective marker of peripheral arterial disease. 10

The prevalence of subclavian artery stenosis rises from 1.4 % in individuals < 50 years to 2.7 % in those > 70 years, illustrating age‑related atherosclerotic progression. 9

The presence of atherosclerotic disease at one vascular territory markedly increases the likelihood of disease at other sites, particularly in elderly patients where overlap of coronary, cerebrovascular, and lower‑extremity disease is common. 10

Circulation, 2006

Journal of the American College of Cardiology, 2006

Circulation, 2006

Diabetes Care, 2024

Circulation, 2006

Journal of the American College of Cardiology, 2006

European Heart Journal, 2011